EBITDA Margin % is calculated as EBITDA divided by its Revenue. Bausch Health's EBITDA for the
three
months ended in Mar. 2026 was C$-901 Mil. Bausch Health's Revenue for the
three
months ended in Mar. 2026 was C$3,463 Mil. Therefore, Bausch Health's EBITDA margin for the quarter that ended in Mar. 2026 was -26.03%.
Bausch Health (TSX:BHC) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bausch Health EBITDA Margin % Related Terms
Bausch Health EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Bausch Health's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bausch Health EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bausch Health's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bausch Health's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (TSX:BHC) has a EBITDA Margin % of -26.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bausch Health and its competitors. Over the past decade, Bausch Health's EBITDA Margin % has ranged from 4.18 to 33.89. According to the industry distribution chart, Bausch Health ranks #334 out of 955 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is Bausch Health's EBITDA Margin % too high?
Bausch Health's current EBITDA Margin % is -26.03%. Over the past 10 years, this metric has ranged from a low of 4.18 to a high of 33.89. Based on the distribution chart, Bausch Health ranks #334 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bausch Health has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #334 out of 955 companies for EBITDA Margin %. This puts Bausch Health in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Historically, Bausch Health's own EBITDA Margin % has ranged from 4.18 to 33.89 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current EBITDA Margin % is -26.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (TSX:BHC) is currently considered Possible Value Trap. The stock's GF Value™ is C$11.06, compared to a current price of C$7.10 — trading 35.8% below its estimated fair value. The current EBITDA Margin % is -26.03%. Bausch Health's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bausch Health (TSX:BHC), the current EBITDA Margin % is -26.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (TSX:BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of C$7.10 is trading 35.8% below its estimated GF Value™ of C$11.06.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for TSX:BHC:
EBITDA Margin %: -26.03%
GF Value™: C$11.06 vs. price of C$7.10 (35.8% below fair value)
No single metric tells the full story. See the TSX:BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
64GF Score
Get the complete analysis for TSX:BHC
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:BHC has been successfully added to your 
